VBL Therapeutics: Rises on panel nod to advance study of cancer therapy

Notable Labs

22/02/2021 12:31

** Shares of the drug developer  VBLT.O  rise 20.7% to $3.08
premarket
    ** Co says Data Safety Monitoring Committee greenlights
advancing co's ongoing late-stage registration enabling study of
VB-111, an anti-cancer gene-therapy agent, in recurrent ovarian
cancer  urn:newsml:reuters.com:*:nGNX5VyGsV
    ** Says committee found no safety issues with the trial and
recommended its continuation as planned
    ** Trial enrolling on track in the United States, Europe and
Israel
    ** Up to last close, VBLT stock up ~35% YTD

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))